心源性卒中诊疗的研究进展  

Progress in Diagnosis and Treatment of Cardiogenic Stroke

作　　者：曹誉竞 陈灏[1,2,3,4] 

机构地区：[1]重庆医科大学,重庆 [2]中国科学院重庆绿色智能技术研究院,重庆 [3]中国科学院大学重庆学院,重庆 [4]重庆市人民医院心血管外科,重庆

出　　处：《临床医学进展》2023年第5期7069-7077,共9页Advances in Clinical Medicine

摘　　要：缺血性脑卒中在中国的发病率逐年增加,其中大约20%的缺血性脑卒中是心源性卒中(CES)。心源性卒中的发生是多因素的,近年来随着诊断手段的丰富,为心源性卒中的防治提供了重要帮助。溶栓治疗是急性心源性卒中的治疗基础,另外临床常规口服传统抗凝药物预防血栓形成,新型抗凝药的出现为患者提供了新的抗凝选择,对于不能耐受抗凝药物或伴随心脏手术的患者通过房颤消融术或左心耳闭合术来预防卒中的发现也是当前的研究热点。本文重点对心源性卒中的诊断、防治进行了综述。The incidence of ischemic stroke in China is increasing year by year, and about 20% of ischemic stroke is cardiogenic stroke (CES) and the occurrence of cardiogenic stroke is multifactorial. In re-cent years, with the enrichment of diagnostic methods, it has provided important assistance for the prevention and treatment of cardiogenic stroke. Thrombolytic therapy is the basis for the treat-ment of acute cardiogenic stroke. In addition, traditional oral anticoagulants are routinely used in clinical practice to prevent thrombosis. The emergence of new anticoagulants provides patients with new anticoagulant options. The discovery of preventing stroke through atrial fibrillation abla-tion or left atrial appendage closure for patients who cannot tolerate anticoagulants or are accom-panied by cardiac surgery is also a current research focus. This article focuses on the diagnosis, prevention, and treatment of cardiogenic stroke.

关 键 词：心源性卒中 心房颤动 口服抗凝药物 房颤消融 左心耳闭合 

分 类 号：R54[医药卫生—心血管疾病]